November 2021
"Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative deal with California-based NASDAQ-quoted business Neurocrine Biosciences.
The vision is to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders.
Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023."